Description
RP3 is currently under investigation for the treatment of colorectal cancer and has shown promising results in early-stage clinical trials. It may be used as a single agent or in combination with other therapies, but its role in the management of colorectal cancer remains to be determined based on ongoing research.
Mechanism of Action
RP3 is an investigational agent that targets specific pathways involved in colorectal cancer progression, though the exact mechanism of action has not been fully elucidated and requires further research.
Side Effects
Nausea; Fatigue; Diarrhea; Hematological toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05733611
med_phase_prefix2
Terminated
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC